Cuba vs Moldova: Life science patents granted, by technology
Cuba
17 patents
in 2023
Moldova
15 patents
in 2023
Cuba rank
30th
Moldova rank
33rd
Life science patents granted, by technology over time
- Cuba
- Moldova
How they compare
Cuba currently reports 17 patents against 15 patents in Moldova, a difference of 2 patents.
That makes Cuba's figure about 1.1 times Moldova's.
The two have swapped places 5 times across 24 shared years of data; in 1995 it was Moldova ahead.
Cuba ranks 30th and Moldova ranks 33rd of 64 countries.
Across the 4 decades both report, Cuba averaged higher in 2 and Moldova in 2.
Head to head by decade
| Decade | Cuba | Moldova | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 1 patents | 22 patents | 21 patents | Moldova |
| 2000s | 9.38 patents | 24.5 patents | 15.12 patents | Moldova |
| 2010s | 27.5 patents | 20 patents | 7.5 patents | Cuba |
| 2020s | 20.25 patents | 19.75 patents | 0.5 patents | Cuba |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher life science patents granted, by technology, Cuba or Moldova?
- Cuba, at 17 patents against 15 patents in Moldova as of 2023.
- What is the difference in life science patents granted, by technology between Cuba and Moldova?
- 2 patents, with Cuba ahead.
- How many years of comparable data are there for Cuba and Moldova?
- 24 years are reported by both, from 1995 to 2023.
- How do Cuba and Moldova rank globally for life science patents granted, by technology?
- Cuba ranks 30th and Moldova ranks 33rd of 64 countries.
- Where does this data come from?
- World Intellectual Property Organization (WIPO) (2025) – processed by Our World in Data, published as Life science patents granted, by technology. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of pharmaceutical patents granted by the filing office in a given year. Pharmaceutical patents typically cover new drugs, biological treatments or vaccines.